Stock Financial Ratios, Dividends, Split History

ANTX / Anthem, Inc., 5.25% Equity Units due 5/1/2018 financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)14,530.27
Enterprise Value ($M)28,660.57
Book Value ($M)27,012.40
Book Value / Share105.71
Price / Book0.54
NCAV ($M)-9,313.90
NCAV / Share-36.45
Price / NCAV-1.56
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 267,800,000
Preferred Stock Shares Outstanding 0
Weighted Average Number Diluted Shares Outstanding Adjustment 6,300,000
Weighted Average Number Of Shares Outstanding Basic 261,500,000
Common Shares Outstanding 255,721,900
Common Stock Shares Outstanding 256,084,913
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.08
Return on Assets (ROA)0.06
Return on Equity (ROE)0.15
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.49
Income Statement (mra) ($M)
Sales Revenue Services Net5,380,400,000.00
Insurance Services Revenue89,061,200,000.00
Operating Income4,175.40
Net Income3,842.80
Earnings Per Share Basic14.70
Earnings Per Share Diluted14.35
Cash Flow Statement (mra) ($M)
Cash From Operations4,184.80
Cash from Investing-5,082.40
Cash from Financing-5,082.40
Identifiers and Descriptors
Central Index Key (CIK)1156039

Split History

Stock splits are used by Anthem, Inc., 5.25% Equity Units due 5/1/2018 to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

11h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

How Will Membership Affect UnitedHealth's (UNH) Q2 Earnings?

2018-07-16 zacks
UnitedHealth Group Inc.’s (UNH - Free Report) second-quarter earnings should be partially offset by a decline in enrollment or the number of customers served in the second quarter. Going by the Zacks Consensus Estimate, total medical membership should be 48.89 billion members, down 1.2% year over year. (8-0)

Centene (CNC) Hits 52 Week High: Is Further Upside Left?

2018-07-06 zacks
On Jul 5, Centene Corp.’s (CNC - Free Report) shares hit a 52 week high of $128.02, ending the day a tad lower at $128.00. (4-0) featured highlights include: Anthem, Merit Medical, Boston Scientific, Grand Canyon and PetMed

2018-06-29 zacks
Chicago, IL – June 29, 2018 - Stocks in this week’s article Anthem Inc. (ANTM - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) , Boston Scientific Corp. (BSX - Free Report) , Grand Canyon Education, Inc. (LOPE - Free Report) and PetMed Express, Inc. (PETS - Free Report) . (93-0)

7 GARP Stocks to Scoop Up for Maximum Returns

2018-06-28 zacks
If you’re looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy. It helps an investor gain exposure to stocks that are undervalued and have impressive growth prospects. However, one should not confuse GARP investing with the blend strategy. While the blend strategy promotes investment in both value and growth stocks, GARP investing requires both value and growth features in a single stock. (87-0)

Sky-High Deductibles Broke the U.S. Health Insurance System - Bloomberg

2018-06-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (132-0)

CUSIP: 036752202